TP53 and breast carcinoma: MonoHER alone showed minimal cytotoxicity, suggesting a priming rather than direct killing effect.<h4>Conclusion</h4>MonoHER modestly sensitize only p53-proficient breast cancer cells to radiation by stabilizing and activating p53, highlighting its potential as an adjuvant radiosensitizer.